ONCE-DAILY ROFLUMILAST CREAM 0.15% FOR ATOPIC DERMATITIS: POOLED RESULTS: FROM INTEGUMENT-1/2 PHASE 3 TRIALS

被引：0
|
作者：
Eichenfield, L.
Boguniewicz, M.
Simpson, E.
Blauvelt, A.
Gooderham, M.
Lain, E.
Chu, D.
Higham, R.
机构：
来源：
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY | 2023年 / 131卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P284
引用
收藏
页码：S91 / S91
页数：1
相关论文
共 50 条
  • [1] Once-daily roflumilast cream 0.15% for atopic dermatitis: pooled results from INTEGUMENT-1/2 phase 3 trials
    Eichenfield, Lawrence F.
    Boguniewicz, Mark
    Simpson, Eric L.
    Blauvelt, Andrew
    Gooderham, Melinda
    Lain, Edward
    Chu, David H.
    Higham, Robert C.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II10 - II11
  • [2] Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials
    Simpson, Eric L.
    Eichenfield, Lawrence F.
    Alonso-Llamazares, Javier
    Draelos, Zoe D.
    Ferris, Laura K.
    Forman, Seth B.
    Gooderham, Melinda
    Gonzalez, Mercedes E.
    Hebert, Adelaide A.
    Kircik, Leon H.
    Lomaga, Mark
    Moore, Angela
    Papp, Kim A.
    Prajapati, Vimal H.
    Hanna, Diane
    Snyder, Scott
    Krupa, David
    Burnett, Patrick
    Almaraz, Erin
    Higham, Robert C.
    Chu, David H.
    Berk, David R.
    JAMA DERMATOLOGY, 2024, 160 (11) : 1161 - 1170
  • [3] Pooled efficacy, patient-reported outcomes, and safety of roflumilast cream 0.15% from the INTEGUMENT-1 and INTEGUMENT-2 phase 3 trials of adults and children with atopic dermatitis
    Simpson, Eric
    Boguniewicz, Mark
    Eichenfield, Lawrence
    Gonzales, Mercedes E.
    Hebert, Adelaide A.
    Prajapati, Vimal H.
    Gooderham, Melinda
    Krupa, David
    Chu, David H.
    Higham, Robert C.
    Berk, David R.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [4] Efficacy and safety of roflumilast cream 0.15% in adults and children aged=6 years with mild to moderate atopic dermatitis in two phase 3 trials (INTEGUMENT-1 and INTEGUMENT-2)
    Simpson, Eric
    Eichenfield, Lawrence
    Gooderham, Melinda
    Gonzalez, Mercedes E.
    Hebert, Adelaide
    Papp, Kim
    Prajapati, Vimal
    Krupa, David
    Burnett, Patrick
    Berk, David
    Higham, Robert
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [5] Efficacy and safety of once-daily roflumilast cream 0.3% in patients with knee/elbow involvement: Pooled results from phase 3 trials (DERMIS-1 and DERMIS-2)
    Ferris, Laura K.
    Draelos, Zoe D.
    Hebert, Adelaide A.
    Lynde, Charles W.
    Pariser, David M.
    Papp, Kim A.
    Yamauchi, Paul S.
    Feng, Amy
    Higham, Robert C.
    Burnett, Patrick
    Berk, David R.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB162 - AB162
  • [6] Pooled efficacy and safety results from the DERMIS-1 and DERMIS-2 phase 3 trials of once-daily roflumilast cream 0.3% for treatment of chronic plaque psoriasis
    Lebwohl, Mark
    Gooderham, Melinda J.
    Guenthner, Scott T.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB93 - AB93
  • [7] Pooled efficacy and safety results from the DERMIS-1 and DERMIS-2 phase 3 trials of once-daily roflumilast cream 0.3% by baseline body surface area
    Gold, Linda Stein
    Bagel, Jerry
    Del Rosso, James
    Green, Lawrence J.
    Lebwohl, Mark
    Kircik, Leon H.
    Feng, Amy
    Snyder, Scott
    Higham, Robert C.
    Burnett, Patrick
    Berk, David R.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB192 - AB192
  • [8] EFFICACY AND SAFETY OF ROFLUMILAST CREAM 0.15% IN ADULTS AND CHILDREN AGED 6 AND OLDER WITH MILD TO MODERATE ATOPIC DERMATITIS IN TWO PHASE 3 INTEGUMENT TRIALS
    Simpson, E.
    Eichenfield, L. F.
    Gooderham, M.
    Gonzalez, M.
    Hebert, A. A.
    Papp, K. A.
    Prajapati, V
    Krupa, D.
    Burnett, P.
    Berk, D. R.
    Higham, R.
    VALUE IN HEALTH, 2023, 26 (06) : S40 - S40
  • [9] Efficacy and safety of once-daily roflumilast cream 0.05% in pediatric patients 2 to 5 years of age with mild to moderate atopic dermatitis (INTEGUMENT-PED): a phase 3 randomized controlled trial
    Eichenfield, Lawrence
    Browning, John
    Funk, Tracy
    Gonzalez, Mercedes E.
    Hebert, Adelaide A.
    Lee, Mark
    Prajapati, Vimal H.
    Serrao, Rocco
    Swanson, Lisa
    Higham, Robert
    Berk, David
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [10] PATIENT-REPORTED OUTCOMES AND FAMILY IMPACT WITH ROFLUMILAST CREAM IN ATOPIC DERMATITIS: POOLED PHASE 3 RESULTS
    Simpson, E.
    Boguniewicz, M.
    Eichenfield, L.
    Geng, B.
    Prajapati, V.
    Friedlander, S. Fallon
    Berk, D.
    Chu, D.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2024, 133 (06) : S9 - S9
12345